- Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 studyShi, Yuankai; Chen, Gongyan; Wang, Xiang; Liu, Yunpeng; Wu, Lin; Hao, Yanrong; Liu, Chunling; Zhu, Shuyang; Zhang, Xiaodong; Li, Yuping; Liu, Jiwei; Cao, Lejie; Cheng, Ying; Zhao, Hui; Zhang, Shucai; Zang, Ai-min; Cui, Jiuwei; Feng, Jian; Yang, Nong; Hu, JieAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Central nervous system efficacy of furmonertinib versus gefitinib in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study.Chen, Gongyan; Wang, Xiang; Liu, Yunpeng; Wu, Lin; Hao, Yanrong; Liu, Chunling; Zhu, Shuyang; Zhang, Xiaodong; Li, Yuping; Liu, Jiwei; Cao, Lejie; Cheng, Ying; Zhao, Hui; Zhang, Shucai; Zang, Aimin; Cui, Jiuwei; Feng, Jian; Liu, Fei; Gu, Chuan; Shi, YuankaiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 2
- Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyShi, Yuankai*; Chen, Gongyan; Wang, Xiang; Liu, Yunpeng; Wu, Lin; Hao, Yanrong; Liu, Chunling; Zhu, Shuyang; Zhang, Xiaodong; Li, Yuping; Liu, Jiwei; Cao, Lejie; Cheng, Ying; Zhao, Hui; Zhang, Shucai; Zang, Aimin; Cui, Jiuwei; Feng, Jian; Yang, Nong; Liu, Fei; Jiang, Yong; Gu, ChuanLancet Respiratory Medicine, 2022, 10(11): 1019-1028.被引 45
会议论文
Furmonertinib versus gefitinib in treatment-naive EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG)
3被引18阅读
